Brea Swihart, NP
Family · Augusta, MENPI 1659669042
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,094 of the $5,181 with a category attached, or 79.0%. It is spread thinly across 21 manufacturers, the largest accounting for just 23.0% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in ME with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 179 payments — averaging $28.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Celltrion USA Inc.$820
- Gilead$574
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$505
- Johnson & Johnson$478
- Takeda Pharmaceuticals U.S.A., Inc.$348
- plus $1K from 15 others
What the payments were for
- Consulting fees$80015%
- Food & beverage$4,09479%
- Education$2866%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 54 | $1,189 |
| Celltrion USA Inc. | 2 | $820 |
| Gilead | 15 | $574 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 41 | $505 |
| Johnson & Johnson(2 entities) | 14 | $478 |
| Takeda Pharmaceuticals U.S.A., Inc. | 12 | $348 |
| Madrigal Pharmaceuticals | 6 | $250 |
| Novo Nordisk | 8 | $166 |
| Intercept Pharmaceuticals, Inc. | 2 | $138 |
| Apollo Endosurgery US Inc | 1 | $134 |
| Lilly USA, LLC | 6 | $132 |
| Regeneron Healthcare Solutions, Inc. | 2 | $102 |
| Nestle Healthcare Nutrition Inc. | 5 | $100 |
| Bristol Myers Squibb | 3 | $60 |
| Pfizer | 2 | $50 |
| Aimmune Therapeutics, Inc. | 1 | $33 |
| Ipsen Biopharmaceuticals, Inc | 1 | $29 |
| Merck | 1 | $22 |
| Mallinckrodt Hospital Products Inc. | 1 | $17 |
| Sanofi | 1 | $17 |
| Boehringer Ingelheim | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ZYMFENTRA$800
- Epclusa$237
- REZDIFFRA$146
- OverStitch Endoscopic Suturing System$134
- OCALIVA$123
How this compares
$5,181 in reported general payments places this provider in the 95th percentile of 545 family providers in Maine.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 31 | $834,528 |
| XifaxanRifaximin | 25 | $82,940 |
| LinzessLinaclotide | 11 | $15,332 |
| Mesalamine | 19 | $8,840 |
| DexilantDexlansoprazole | 14 | $8,484 |
| Dexlansoprazole DrDexlansoprazole | 18 | $4,468 |
| Colestipol Hcl | 16 | $3,483 |
| Rabeprazole Sodium | 23 | $3,417 |
| Omeprazole | 98 | $1,896 |
| Sucralfate | 14 | $1,328 |
| LoperamideLoperamide Hcl | 19 | $1,121 |
| Pantoprazole Sodium | 43 | $964 |
| Famotidine | 83 | $912 |
| Ondansetron OdtOndansetron | 17 | $871 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 25 | $742 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonStelara | $478 | $834,52831 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $505 | $82,94025 claims |
| AbbVieLinzess | $1,189 | $15,33211 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $348 | $8,48414 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 545 family providers in Maine.
Other family in Augusta
- Dawn LevasseurAugusta$3K
- Amanda WilliamsAugusta$3K
- Lynne BowdenAugusta$2K
- Mia RapollaFalmouth$193K
- Patti DupreyKennebunk$35K
- Amanda WilliamsPortland$8K
- Jamie PiacentiniScarborough$6K
- Rosemary PainePortland$6K
- Kristen Schroeder-CyrBrunswick$5K
- Liana KellyBrunswick$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.